The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-Labelled, Non-Comparative, Multicentric, Phase IV Trial.

Trial Profile

The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-Labelled, Non-Comparative, Multicentric, Phase IV Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 12 May 2009 Actual patient number (251) added as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Planned number of patients changed from 250 to 251 as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top